경장 스텐트 시장 : 세계 예측(2026-2032년)

The Enteral Stents Market is projected to grow by USD 1,378.39 million at a CAGR of 5.47% by 2032.

Enteral Stents: Executive Summary

Enteral stents are medical devices used to restore or maintain gastrointestinal luminal patency when obstruction, narrowing, or impaired passage affects patient care. Their clinical value is linked to timely diagnosis, appropriate device selection, procedural expertise, and coordinated follow-up. Demand conditions are shaped by gastrointestinal disease burden, oncology pathways, hospital infrastructure, endoscopy capacity, reimbursement, and regulatory requirements.

Clinical Pathways and Device Design Are Reshaping Enteral Stenting

The enteral stents landscape is evolving through greater emphasis on minimally invasive palliation, bridge-to-surgery strategies, and individualized treatment planning. Clinicians increasingly weigh stent diameter, length, covering, removability, migration risk, tissue ingrowth, delivery-system performance, and compatibility with subsequent interventions. Improvements in endoscopic imaging, fluoroscopic support, multidisciplinary case review, and post-procedure surveillance are also influencing how enteral stenting is integrated into care pathways.

Artificial Intelligence Strengthens Planning, Detection, and Follow-Up

Artificial intelligence can support enteral stent services by improving image interpretation, identifying obstruction patterns, assisting lesion localization, and helping prioritize cases for specialist review. Predictive tools may also aid risk stratification for migration, re-obstruction, adverse events, or repeat intervention when validated against clinically representative datasets. Safe adoption requires transparent performance evaluation, human oversight, protection of patient data, interoperability with endoscopy and hospital systems, and monitoring for bias across patient populations and care settings.

Regional Insights: Access and Care Delivery Vary Widely

North America combines advanced endoscopy infrastructure with established multidisciplinary oncology and gastroenterology pathways, while Latin America experiences uneven access related to referral networks, financing, and specialist availability. Europe benefits from mature clinical guidance and cross-border regulatory alignment, although adoption and reimbursement differ by country. The Middle East is expanding specialized hospital capacity in selected hubs, whereas Africa faces broader constraints in diagnostic services, trained personnel, device procurement, and follow-up continuity. Asia-Pacific presents substantial diversity: technologically advanced systems coexist with settings where affordability, rural access, and procedural capacity remain central challenges.

Group Insights: Policy Alignment Supports Consistent Clinical Practice

ASEAN members show differing levels of endoscopy capacity, regulatory maturity, and health-system financing, making regional cooperation valuable for training and procurement. BRICS countries span large and varied patient populations, with opportunities to strengthen domestic manufacturing, referral pathways, and specialist education while addressing uneven access. The European Union benefits from coordinated regulatory structures but retains national differences in reimbursement and service delivery. G7 health systems generally possess strong tertiary-care capabilities and data infrastructure, while GCC countries continue developing specialized hospital networks. NATO members represent diverse health systems, yet preparedness, supply continuity, and interoperable clinical standards remain relevant considerations.

Country Insights: National Systems Shape Enteral Stent Adoption

Australia and Canada rely on geographically distributed referral systems, making specialist access and procedural concentration important. Brazil and Mexico face variation between major urban centers and underserved areas. China and India combine advanced tertiary hospitals with substantial regional differences in capacity and affordability. France, Germany, Italy, Spain, and the United Kingdom operate within established European clinical environments, but procurement, reimbursement, and referral organization differ nationally. Japan and South Korea have sophisticated endoscopy capabilities supported by strong hospital infrastructure. Russia's access is influenced by regional healthcare disparities, procurement conditions, and specialist availability. The United States has extensive advanced-care capacity, with utilization shaped by payer policies, institutional protocols, and multidisciplinary practice.

Priorities for Leaders: Improve Selection, Capability, and Continuity of Care

Industry leaders should prioritize evidence-based device selection, clinician training, and standardized pathways for patient assessment, consent, placement, and surveillance. Hospitals can improve outcomes by using multidisciplinary review for complex cases, tracking technical and clinical endpoints, and establishing escalation plans for migration, obstruction, bleeding, or perforation. Suppliers and care organizations should support interoperable documentation, transparent product information, responsible post-market monitoring, and training that reflects local skill levels. Expansion into underserved settings should be paired with referral coordination, maintenance of endoscopic equipment, and realistic plans for follow-up and repeat intervention.

Research Methodology: Evidence-Led Assessment of Enteral Stent Services

This executive summary uses a structured qualitative assessment of enteral stenting, integrating clinical-care considerations, technology trends, health-system conditions, regulatory context, and geographic variation. Regional, group, and country narratives are organized around access to diagnosis, specialist expertise, endoscopy infrastructure, reimbursement, procurement, and continuity of care. Artificial intelligence observations are limited to established or plausible clinical applications that require validation. No market estimates, market sizing, market shares, forecasts, or company-specific claims are included.

Conclusion: Clinical Integration Will Define Future Value

The enteral stents field is being shaped less by device availability alone than by the quality of clinical integration surrounding each procedure. Appropriate patient selection, experienced teams, reliable equipment, coordinated oncology and gastroenterology pathways, and structured follow-up are central to safe and effective use. Regional and national differences make adaptable implementation essential, while validated digital tools and artificial intelligence may strengthen decision support when deployed with clinical governance and data safeguards.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Enteral Stents Market, by Product Type

• 7.1. Introduction
• 7.2. Biodegradable Stents
  • 7.2.1. Poly-L-Lactic Acid
  • 7.2.2. Polydioxanone
• 7.3. Plastic Stents
  • 7.3.1. Double-Pigtail
  • 7.3.2. Single-Pigtail
• 7.4. Self-Expanding Metal Stents
  • 7.4.1. Nitinol
  • 7.4.2. Stainless Steel

8. Enteral Stents Market, by Material

• 8.1. Introduction
• 8.2. Biodegradable Polymer
• 8.3. Metal Alloy
• 8.4. Plastic

9. Enteral Stents Market, by Application

• 9.1. Introduction
• 9.2. Biliary
• 9.3. Colorectal
• 9.4. Esophageal
• 9.5. Gastrointestinal

10. Enteral Stents Market, by End User

• 10.1. Introduction
• 10.2. Ambulatory Surgical Centers
• 10.3. Hospitals
• 10.4. Specialty Clinics

11. Enteral Stents Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Online
• 11.3. Offline

12. Enteral Stents Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Enteral Stents Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Enteral Stents Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Ace Medical Devices Pvt. Ltd.
• 16.3. Allium Medical Solutions, Inc.
• 16.4. Alvimedica, Inc.
• 16.5. B. Braun Melsungen AG
• 16.6. Becton, Dickinson and Company
• 16.7. BIOTRONIK SE & Co. KG
• 16.8. Boston Scientific Corporation
• 16.9. Cardinal Health, Inc.
• 16.10. CONMED Corporation
• 16.11. Cook Medical LLC
• 16.12. ELLA-CS s.r.o.
• 16.13. Endo-Flex GmbH
• 16.14. Endologix, Inc.
• 16.15. Genoss Co., Ltd.
• 16.16. Hobbs Medical, Inc.
• 16.17. Hyundai Medical Co., Ltd.
• 16.18. Lepu Medical Technology Co., Ltd.
• 16.19. M.I. Tech Co., Ltd.
• 16.20. Meril Life Sciences Private Limited
• 16.21. Merit Medical Systems, Inc.
• 16.22. MicroPort Scientific Corp
• 16.23. MITRA Industries Private Limited
• 16.24. Olympus Corporation
• 16.25. S&G Biotech, Inc.
• 16.26. Shaili Endoscopy Co., Ltd.
• 16.27. SINOMED Co., Ltd.
• 16.28. Taewoong Medical Co., Ltd.

17. Key Experts